Menostar (estradiol) transdermal system
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
- Known anaphylactic reaction or angioedema with Menostar
- Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders
WARNINGS AND PRECAUTIONS
- Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema.